Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS

Table 1 Baseline Characteristics of Participants ¹

	Standard Care N = 26	In-person N = 26	mHealth N = 26	Overall p-value
Male N(%)	11 (42.3%)	16 (61.5%)	20 (76.9%)	0.04
Age (mean ± SD yrs)	57.5 ± 10.9	58.5 ± 11.9	54.7 ± 11.5	0.47
White Not-Hispanic N(%)	24 (92.3%)	25 (96.2%)	25 (96.2%)	0.77
Bulbar Onset N(%)	3 (11.5%)	2 (7.7%)	4 (15.4%)	0.69
ALSFRS-R (mean ± SD)	36.7 ± 5.4	34.9 ± 6.7	37.4 ± 6.2	0.35
Months since symptom onset (mean ± SD)	22.3 (18.0)	26.1 (16.8)	27.1 (18.9)	0.60
BMI (mean ± SD kg/m²)	26.8 ± 5.1	25.7 ± 4.1	26.0 ± 4.5	0.70
Weight loss since diagnosis (mean ± SD kg)	3.4 ± 5.5	6.3 ± 7.1	2.1 ± 3.4	0.03
Weight loss since max weight (mean ± SD kg)	7.8 ± 9.4	10.4 ± 10.7	6.0 ± 6.7	0.23
Change in BMI since diagnosis (mean ± SD kg/m²)	1.2 ± 1.9	2.2 ± 2.6	0.6 ± 1.0	0.01

¹ Baseline characteristics of participants are shown according to treatment group in frequency (N) and percent or mean and standard deviation (SD); Bulbar onset = symptoms of ALS beginning in the cranial nerves; ALSFRS-R = ALS Functional Rating Scale-Revised; BMI = body mass index

ISSN: 1471-2377